JAN 27, 2021 8:30 AM PST

Do Vaccines Work Against New Covid Variants?

WRITTEN BY: Annie Lennon

The SARS-CoV-2 virus is mutating faster than scientists previously thought. As such, pharmaceutical companies are now scrambling to both test whether their vaccines are effective against new variants of the virus and to develop booster shots. 

Currently, both Moderna and Pfizer-BioNTech have said that their vaccines appear to be effective against the new variants of coronavirus in the UK and South Africa, although they are both less protective against the South African variant. As such, protection against this variant may disappear more quickly unless further measures are taken. 

To this end, Moderna has started to develop a new form of its vaccine to be used as a booster shot against the South African variant. While Moderna's chief medical officer, Dr. Tal Zaks, says that they hope it will not be necessary, they are developing it as 'an insurance policy'. The company has also said that it plans to begin testing whether giving patients a third shot of its original vaccine may help fend off new variants. 

Moreover, in a recent experiment that is yet to be published or peer-reviewed, Moderna examined blood samples from eight people, and two monkeys had received two doses of their vaccine. While they found that the vaccine was similarly effective against both the original and British variant of the virus, antibodies produced by the vaccine appeared to be six times less effective against the South African variant. Nevertheless, the company said that their antibodies remained above minimum protective levels. 

Meanwhile, BioNTech is now in discussions with regulators to define the types of clinical trials needed worldwide to authorize a new version of the Pfizer-BioNTech vaccine that would be better able to fend off the South African variant. Although the company says it could develop a new vaccine capable of tackling new variants in just six weeks, the Food and Drug Administration is yet to comment on policy for authorizing such 'updated' vaccines. 

 

Sources: bioRxivBBCThe New York Times

About the Author
  • Science writer with keen interests in technology and behavioral biology. Her current focus is on the interplay between these fields to create meaningful interactions, applications and environments.
You May Also Like
NOV 28, 2020
Microbiology
Potential Treatment ID'ed for Emerging Viral Disease
NOV 28, 2020
Potential Treatment ID'ed for Emerging Viral Disease
A mosquito-borne virus called VEEV has been emerging in South America. It causes symptoms that make it difficult to dist ...
NOV 30, 2020
Microbiology
Common Antibiotic Could be Effective Zika Treatment
NOV 30, 2020
Common Antibiotic Could be Effective Zika Treatment
Zika virus cause a devastating epidemic in 2015, and led to the birth of hundreds of children that had congenital brain ...
DEC 01, 2020
Drug Discovery & Development
Breakthrough Drug Reduces Inflammation and Pain in Arthritis
DEC 01, 2020
Breakthrough Drug Reduces Inflammation and Pain in Arthritis
Researchers from the Universities of Oxford and Birmingham in the UK have found that otilimab can reduce infla ...
DEC 20, 2020
Genetics & Genomics
A Repurposed Drug Can Treat a Genetic Disorder
DEC 20, 2020
A Repurposed Drug Can Treat a Genetic Disorder
Some researchers have sought to treat genetic diseases by correcting the mutation. But it may be possible to use another ...
JAN 03, 2021
Drug Discovery & Development
How Psychedelic Salvinorin A Works in the Brain
JAN 03, 2021
How Psychedelic Salvinorin A Works in the Brain
Despite increasing interest in hallucinogens, the effects of Salvinorin A, a drug used in Native Mexican rituals, have r ...
FEB 10, 2021
Drug Discovery & Development
Genetics Affect Response to Cancer Immunotherapy
FEB 10, 2021
Genetics Affect Response to Cancer Immunotherapy
Researchers have found that genetic factors may dictate as much as 20% of the efficacy of checkpoint inhibitors, a kind ...
Loading Comments...